# Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age

> **NCT05956821** · PHASE1,PHASE2 · RECRUITING · sponsor: **University of Miami** · enrollment: 20 (estimated)

## Conditions studied

- Glioblastoma Multiforme
- Anaplastic Astrocytoma
- Fibrillary Astrocytomas
- Oligodendroglioma
- Diffuse Intrinsic Brainstem Glioma
- Diffuse Intrinsic Pontine Glioma
- DIPG Brain Tumor
- H3 K27M

## Interventions

- **DRUG:** SIACI of cetuximab and bevacizumab

## Key facts

- **NCT ID:** NCT05956821
- **Lead sponsor:** University of Miami
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-19
- **Primary completion:** 2029-10-01
- **Final completion:** 2029-12-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05956821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05956821, "Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05956821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*